Product Information
OMEPRAZOLE-BICARB 40-1,100 CAP is a generic product labeled by Cipla USA Inc., priced at $0.5622 per EA under NDC 69097091402. Its NADAC has been published 504 times since Feb 8, 2017.
FDA first approved this application on Dec 6, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
40; 1100 mg/1; mg/1
Manufacturer
Cipla USA Inc.NDC
69097091402
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
OMEPRAZOLE; SODIUM BICARBONATEApproval Type
Generic (ANDA)
FDA Application
ANDA207476FDA Approved
12/6/2016
TE Code
AB
On Market Since
1/30/2017
Pharmacological Classes
Price Statistics
The NADAC for OMEPRAZOLE-BICARB 40-1,100 CAP has been published 504 times since Feb 8, 2017, and over the history we have for it it has declined 98.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5622 per EA |
|---|---|
| All-time high | $30.7203 (Mar 15, 2017) |
| All-time low | $0.5100 (Jan 21, 2026) |
| 52-week high | $0.6725 |
| 52-week low | $0.5100 |
| Median price | $1.1724 |
| Average price | $2.8944 |
| Largest weekly change | +61.3% (Jan 17, 2024) |
| Weeks tracked | 504 |
| Tracking since | Feb 8, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the omeprazole sodium bicarbonate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cipla USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
omeprazole sodium bicarbonate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Proton Pump Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OMEPRAZOLE-BICARB 40-1,100 CAP?
The current National Average Drug Acquisition Cost (NADAC) for OMEPRAZOLE-BICARB 40-1,100 CAP, manufactured by Cipla USA Inc., is $0.5622 per EA (NDC 69097091402), effective Sep 30, 2026.
How has the price of OMEPRAZOLE-BICARB 40-1,100 CAP changed over time?
Over the history we have for it, the NADAC for OMEPRAZOLE-BICARB 40-1,100 CAP has declined 98.1%. It has been tracked across 504 weekly CMS publications since Feb 8, 2017.
What are the highest and lowest recorded NADAC prices for OMEPRAZOLE-BICARB 40-1,100 CAP?
Since Feb 8, 2017, the NADAC for OMEPRAZOLE-BICARB 40-1,100 CAP has ranged from a low of $0.5100 (Jan 21, 2026) to a high of $30.7203 (Mar 15, 2017), with a median of $1.1724 per EA.
Are there cheaper alternatives to OMEPRAZOLE-BICARB 40-1,100 CAP?
No other NADAC-published product currently shares the active ingredient and strength of OMEPRAZOLE-BICARB 40-1,100 CAP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures OMEPRAZOLE-BICARB 40-1,100 CAP?
OMEPRAZOLE-BICARB 40-1,100 CAP (NDC 69097091402) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.